跳到正文
原文
Nature 综合主刊· Thomas D. Jackson·· 9 天前AI 评分35

线粒体蛋白导入缺陷增强肿瘤免疫原性

Mitochondrial protein import defects enhance tumour immunogenicity

AI 导读

研究发现,线粒体蛋白导入缺陷可增强肿瘤免疫原性。该研究团队将相关蛋白质组学数据上传至PRIDE数据库(PXD069846),并公布了RNA-seq数据(GSE347225和GSE320547)。这些数据表明,线粒体功能异常可能通过改变肿瘤微环境,提高其免疫原性。

正文

Data availability

Proteomics data have been deposited to the Proteomics Identifications Database (PRIDE) under the accession number PXD069846. RNA-seq data have been deposited to the Gene Expression Omnibus (GEO) under accession numbers GSE347225 (RNA-seq of YUMM1.7 tumours inoculated in C57BL/6 mice) and GSE320547 (RNA-seq of B16-BL6 and YUMM1.7 cells cultured in vitro). Processed datasets for RNA-seq, proteomics and metabolomics are available as Supplementary Tables. Uncropped blots are provided in Supplementary Fig. 1. For proteomics analysis, the mouse reference proteome (UP000000589) was downloaded from Uniprot in May 2023. The mouse reference genome GRCm39 was used for mapping of RNA-seq reads. Source data are provided with this paper.

References

  1. Galassi, C., Chan, T. A., Vitale, I. & Galluzzi, L. The hallmarks of cancer immune evasion. Cancer Cell 42, 1825–1863 (2024).

    Article  CAS  PubMed  Google Scholar 

  2. König, T. & McBride, H. M. Mitochondrial-derived vesicles in metabolism, disease, and aging. Cell Metab. 36, 21–35 (2024).

    Article  PubMed  Google Scholar 

  3. Liang, J. et al. Selective deficiency of mitochondrial respiratory complex I subunits Ndufs4/6 causes tumor immunogenicity. Nat. Cancer 6, 323–337 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Mangalhara, K. C. et al. Manipulating mitochondrial electron flow enhances tumor immunogenicity. Science 381, 1316–1323 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Yuan, S. et al. VDAC2 loss elicits tumour destruction and inflammation for cancer therapy. Nature 640, 1062–1071 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Rath, S. et al. MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotations. Nucleic Acids Res. 49, D1541–D1547 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Endo, T. & Wiedemann, N. Molecular machineries and pathways of mitochondrial protein transport. Nat. Rev. Mol. Cell Biol. 26, 848–867 (2025).

    Article  CAS  PubMed  Google Scholar 

  8. Petitprez, F. et al. The murine microenvironment cell population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. Genome Med. 12, 86 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Holicek, P. et al. Type I interferon and cancer. Immunol. Rev. 321, 115–127 (2024).

    Article  CAS  PubMed  Google Scholar 

  10. Greiner, J. W. et al. Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte α-interferon treatment. Cancer Res. 44, 3208–3214 (1984).

    CAS  PubMed  Google Scholar 

  11. West, A. P. et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature 520, 553–557 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Novotny, M. V., Xu, W., Mulya, A., Janocha, A. J. & Erzurum, S. C. Method for depletion of mitochondria DNA in human bronchial epithelial cells. MethodsX 12, 102497 (2024).

    Article  CAS  PubMed  Google Scholar 

  13. Stetson, D. B., Ko, J. S., Heidmann, T. & Medzhitov, R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134, 587–598 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Hopfner, K.-P. & Hornung, V. Molecular mechanisms and cellular functions of cGAS–STING signalling. Nat. Rev. Mol. Cell Biol. 21, 501–521 (2020).

    Article  CAS  PubMed  Google Scholar 

  15. Newman, L. E. & Shadel, G. S. Mitochondrial DNA release in innate immune signaling. Annu. Rev. Biochem. 92, 299–332 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Xian, H. et al. Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels to activate NLRP3 inflammasome and interferon signaling. Immunity 55, 1370–1385.e8 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Kim, J. et al. VDAC oligomers form mitochondrial pores to release mtDNA fragments and promote lupus-like disease. Science 366, 1531–1536 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. McArthur, K. et al. BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis. Science 359, eaao6047 (2018).

    Article  PubMed  Google Scholar 

  19. Zecchini, V. et al. Fumarate induces vesicular release of mtDNA to drive innate immunity. Nature 615, 499–506 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Miao, R. et al. Gasdermin D permeabilization of mitochondrial inner and outer membranes accelerates and enhances pyroptosis. Immunity 56, 2523–2541.e8 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Rogers, C. et al. Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. Nat. Commun. 10, 1689 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  22. Soubannier, V. et al. A vesicular transport pathway shuttles cargo from mitochondria to lysosomes. Curr. Biol. 22, 135–141 (2012).

    Article  CAS  PubMed  Google Scholar 

  23. Matheoud, D. et al. Parkinson’s disease-related proteins PINK1 and Parkin repress mitochondrial antigen presentation. Cell 166, 314–327 (2016).

    Article  CAS  PubMed  Google Scholar 

  24. McLelland, G.-L., Lee, S. A., McBride, H. M. & Fon, E. A. Syntaxin-17 delivers PINK1/parkin-dependent mitochondrial vesicles to the endolysosomal system. J. Cell Biol. 214, 275–291 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Newman, L. E. et al. Mitochondrial DNA replication stress triggers a pro-inflammatory endosomal pathway of nucleoid disposal. Nat. Cell Biol. 26, 194–206 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Lan, Y. Y., Londoño, D., Bouley, R., Rooney, M. S. & Hacohen, N. Dnase2a deficiency uncovers lysosomal clearance of damaged nuclear DNA via autophagy. Cell Rep. 9, 180–192 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Crameri, J. J. et al. Reduced protein import via TIM23 sort drives disease pathology in TIMM50-associated mitochondrial disease. Mol. Cell. Biol. 44, 226–244 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Murphy, M. P. How mitochondria produce reactive oxygen species. Biochem. J. 417, 1–13 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Garstka, H. L. et al. Import of mitochondrial transcription factor A (TFAM) into rat liver mitochondria stimulates transcription of mitochondrial DNA. Nucleic Acids Res. 31, 5039–5047 (2003).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ott, C. et al. Sam50 functions in mitochondrial intermembrane space bridging and biogenesis of respiratory complexes. Mol. Cell. Biol. 32, 1173–1188 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Wollweber, F., von der Malsburg, K. & van der Laan, M. Mitochondrial contact site and cristae organizing system: a central player in membrane shaping and crosstalk. Biochim. Biophys. Acta 1864, 1481–1489 (2017).

    Article  CAS  Google Scholar 

  32. Kim, M. et al. Immunoproteasome-specific subunit PSMB9 induction is required to regulate cellular proteostasis upon mitochondrial dysfunction. Nat. Commun. 14, 4092 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Nguyen, M. et al. MAPL regulates gasdermin-mediated release of mtDNA from lysosomes to drive pyroptotic cell death. Nat. Cell Biol. https://doi.org/10.1038/s41556-025-01774-y (2025).

  34. Shahrour, M. et al. Mitochondrial epileptic encephalopathy, 3-methylglutaconic aciduria and variable complex V deficiency associated with TIMM50 mutations. Clin. Genet. 91, 690–696 (2017).

    Article  CAS  PubMed  Google Scholar 

  35. Devi, L., Prabhu, B. M., Galati, D. F., Avadhani, N. G. & Anandatheerthavarada, H. K. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer’s disease brain is associated with mitochondrial dysfunction. J. Neurosci. 26, 9057–9068 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Di Maio, R. et al. α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease. Sci. Transl. Med. 8, 342ra378 (2016).

    Google Scholar 

  37. Yano, H. et al. Inhibition of mitochondrial protein import by mutant huntingtin. Nat. Neurosci. 17, 822–831 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Heneka, M. T., Kummer, M. P. & Latz, E. Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 14, 463–477 (2014).

    Article  CAS  PubMed  Google Scholar 

  39. Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783–784 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Yang, X. et al. A public genome-scale lentiviral expression library of human ORFs. Nat. Methods 8, 659–661 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Meerbrey, K. L. et al. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc. Natl Acad. Sci. USA 108, 3665–3670 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Bryant, J. D., Lei, Y., VanPortfliet, J. J., Winters, A. D. & West, A. P. Assessing mitochondrial DNA release into the cytosol and subsequent activation of innate immune-related pathways in mammalian cells. Curr. Protoc. 2, e372 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal 17, 10–12 (2011).

    Article  Google Scholar 

  44. Kim, D., Paggi, J. M., Park, C., Bennett, C. & Salzberg, S. L. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat. Biotechnol. 37, 907–915 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Li, H. et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  46. Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).

    Article  CAS  PubMed  Google Scholar 

  47. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  48. Li, J. et al. TMTpro-18plex: the expanded and complete set of TMTpro reagents for sample multiplexing. J. Proteome Res. 20, 2964–2972 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Navarrete-Perea, J., Yu, Q., Gygi, S. P. & Paulo, J. A. Streamlined tandem mass tag (SL-TMT) protocol: an efficient strategy for quantitative (phospho) proteome profiling using tandem mass tag-synchronous precursor selection-MS3. J. Proteome Res. 17, 2226–2236 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Hughes, C. S. et al. Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. Nat. Protoc. 14, 68–85 (2019).

    Article  CAS  PubMed  Google Scholar 

  51. Schweppe, D. K. et al. Characterization and optimization of multiplexed quantitative analyses using high-field asymmetric-waveform ion mobility mass spectrometry. Anal. Chem. 91, 4010–4016 (2019).

  52. Rad, R. et al. Improved monoisotopic mass estimation for deeper proteome coverage. J. Proteome Res. 20, 591–598 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  53. Eng, J. K., Jahan, T. A. & Hoopmann, M. R. Comet: an open-source MS/MS sequence database search tool. Proteomics 13, 22–24 (2013).

    Article  CAS  PubMed  Google Scholar 

  54. Huttlin, E. L. et al. A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174–1189 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Kong, A. T. et al. MSFragger: ultrafast and comprehensive peptide identification in mass spectrometry-based proteomics. Nat. Methods 14, 513–520 (2017).

  56. Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S. & Ralser, M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat. Methods 17, 41–44 (2020).

    Article  CAS  PubMed  Google Scholar 

  57. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  58. Yuan, M., Breitkopf, S. B., Yang, X. & Asara, J. M. A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat. Protoc. 7, 872–881 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Pang, Z. et al. MetaboAnalyst 6.0: towards a unified platform for metabolomics data processing, analysis and interpretation. Nucleic Acids Res. 52, W398–W406 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  60. Yuan, M. et al. Ex vivo and in vivo stable isotope labelling of central carbon metabolism and related pathways with analysis by LC–MS/MS. Nat. Protoc. 14, 313–330 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We acknowledge all members of the Puigserver laboratory for helpful discussions regarding this study; and the HMS Electron Microscopy Facility and the Beth Israel Deaconess Medical Center Metabolomics cores for their assistance with electron microscopy and metabolomics profiling, respectively.

Funding

T.D.J. was supported by a Cancer Research Institute Irvington Postdoctoral Fellowship (CRI5298). T.V. was supported by National Institutes of Health (NIH) fellowship 1F99CA305428-01 and NIH training grant 1T32GM145407-01. J.M.P. was supported by United Mitochondrial Disease Foundation Research Grant (PF-23-0006). J.A.P. was supported by NIH grant R35 GM156406. P.L.-M. was supported by NIH National Institute of Diabetes and Digestive and Kidney Diseases grant K99DK133502. B.Z. was supported by a postdoctoral fellowship from the American Heart Association (26POST1560860). R.C. acknowledges support from the Dana-Farber Medical Oncology Fellowship Program. This work was funded by the Claudia Adams Barr Program in Cancer Research, Dana-Farber Cancer Institute Innovation Research Funds, NIH grant R01CA181217, the Department of Defense grant CDMRP W81XWH-22-1-0780, the Melanoma Research Foundation and the American Cancer Society (all to P.P.).

Author information

Authors and Affiliations

  1. Department of Cell Biology, Harvard Medical School, Boston, MA, USA

    Thomas D. Jackson, Jonathan M. Palozzi, Christopher D. McGann, Tevis Vitale, Ruth Choa, Joao A. Paulo, Pedro Latorre-Muro, Jonathan G. Van Vranken, Bingsen Zhang, Manisha Yadav, Steven P. Gygi & Pere Puigserver

  2. Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA

    Thomas D. Jackson, Jonathan M. Palozzi, Christopher D. McGann, Tevis Vitale, Ruth Choa, Hieu H. M. Nguyen, Pedro Latorre-Muro, Matthew Ravichandran, Bingsen Zhang, Manisha Yadav & Pere Puigserver

Authors

  1. Thomas D. Jackson
  2. Jonathan M. Palozzi
  3. Christopher D. McGann
  4. Tevis Vitale
  5. Ruth Choa
  6. Hieu H. M. Nguyen
  7. Joao A. Paulo
  8. Pedro Latorre-Muro
  9. Jonathan G. Van Vranken
  10. Matthew Ravichandran
  11. Bingsen Zhang
  12. Manisha Yadav
  13. Steven P. Gygi
  14. Pere Puigserver

Contributions

T.D.J. conceived the study, performed the in vitro and in vivo experiments, prepared the figures and co-wrote the manuscript. J.M.P. designed and performed the confocal microscopy imaging experiments and analysed the associated data. T.V. performed the flow cytometry analysis and bioinformatic analysis of the RNA-seq and metabolomics data. R.C. performed the flow cytometry analysis. H.H.M.N., M.R. and M.Y. performed the in vitro experiments. P.L.-M. performed the mitochondrial respiration measurements. C.D.M., J.A.P., J.G.V.V. and S.P.G. performed and analysed the proteomics experiments. B.Z. assisted with the analysis of the metabolomics data. P.P. conceived the study, provided overall guidance and co-wrote the manuscript.

Corresponding author

Correspondence to Pere Puigserver.

Ethics declarations

Competing interests

The authors declare no competing interests.

Peer review

Peer review information

Nature thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data figures and tables

Extended Data Fig. 1 Characterization of mitochondrial protein import deficient B16-BL6 and YUMM1.7 cells and tumors.

a,b, Immunoblot analysis performed using SDS-PAGE (a) and BN-PAGE (b) of mitochondria isolated from sgNTC, sgAgk, sgTimm10b, sgTimm17b, and sgTimm50-1 B16-BL6 cells. c, In vitro mitochondrial protein import assays assessing the import of radiolabeled COQ9 and OTC into mitochondria isolated from sgNTC, sgTimm50-1, and sgTimm17b B16-BL6 cells. Import was performed for the indicated times, in the absence or presence of FCCP to dissipate membrane potential (ΔΨ) as indicated. Quantification was performed using the mature processed form (‘m’) of each protein, normalized to the intensity of the mature protein in sgNTC cells at 18 min. d, Tumor growth curves of sgNTC, sgAgk (Foxn1nu: n = 5 with sgNTC and sgAgk tumors grown on opposite flanks of each mouse; C57BL/6: n = 9 for sgNTC, n = 10 for sgAgk), sgTimm10b (Foxn1nu: n = 5 with sgNTC and sgTimm10b tumors grown on opposite flanks of each mouse; C57BL/6: n = 5 with sgNTC and sgTimm10b tumors grown on opposite flanks of each mouse), or sgTimm17b (Foxn1nu: n = 5 with sgNTC and sgTimm17b tumors grown on opposite flanks of each mouse; C57BL/6: n = 4 with sgNTC and sgTimm17b tumors grown on opposite flanks of each mouse) B16-BL6 tumors in C57BL/6 or nude Foxn1nu mice. e, Tumor growth curves of sgNTC, sgTimm50-1, or sgTimm50-2 B16-BL6 tumors in C57BL/6 mice, treated with isotype control (IgG) or anti-mouse CD8β antibody to deplete CD8+ T-cells (CD8). n = 9 for sgNTC IgG, n = 10 for sgTimm50-1 IgG, n = 9 for sgTimm50-2 IgG, n = 10 for sgNTC CD8, n = 8 for sgTimm50-1 CD8, n = 10 for sgTimm50-2 CD8. f, Principal component analysis (PCA) of RNA-sequencing datasets from sgNTC (n = 7), sgTimm50-1 (n = 9), or sgTimm50-2 (n = 8) YUMM1.7 tumors inoculated in C57BL/6 mice. g, Functional enrichment analysis performed using differentially expressed genes from RNA-sequencing datasets obtained from bulk tumor RNA isolated from sgNTC (n = 7), sgTimm50-1 (n = 9), or sgTimm50-2 (n = 8) YUMM1.7 tumors from C57BL/6 mice. h,i, qPCR (h) or immunoblot (i) analysis of sgNTC (n = 7), sgTimm50-1 (n = 9), or sgTimm50-2 (n = 8) YUMM1.7 tumors inoculated in C57BL/6 mice. j,k, Immunoblot (j) or qPCR (k) analysis of sgNTC or sgTimm50-2 B16-BL6 tumors inoculated in C57BL/6 mice. n = 10 for both conditions. Data are mean ± s.e.m. (d and e), and mean ± s.d. (h and k). Statistical analysis was performed using two-way ANOVA (d), or two-way ANOVA on log2-transformed fold change values with Tukey’s multiple comparisons test (h), or multiple unpaired two-tailed t tests on log2-transformed fold change values with Holm-Šidak correction for multiple comparisons (k). For clarity, only relevant comparisons are highlighted. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns, not significant. For immunoblot source data, see Supplementary Fig. 1. Exact p-values are provided in source data.

Source data

Extended Data Fig. 2 Tumor immune deconvolution and flow cytometry gating strategy.

a, mMCP-counter (murine Microenvironment Cell Population) scores for different immune cell populations, calculated using YUMM1.7 tumor RNA-sequencing data presented in Fig. 1e. Data are mean ± s.d. Statistical analysis was performed using one-way ANOVA with Dunnett’s multiple comparisons test. b, Representative density plots demonstrating the gating strategy employed for the analysis of tumor-infiltrating T cells in Fig. 1g. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns, not significant. Exact p-values are provided in source data.

Source data

Extended Data Fig. 3 Timm50 depletion induces type-I IFN induction in a variety of cell lines.

a, Heat maps depicting expression of genes associated with the Gene Ontology (GO) term “Cellular response to interferon-beta” (GO:0035458) in sgNTC, sgTimm50-1 or sgTimm50-2 B16-BL6 and YUMM1.7 cells. Expression values are presented as row Z-scores calculated from RNA-seq data. b, Principal component analysis (PCA) of RNA-sequencing datasets from sgNTC, sgTimm50-1, or sgTimm50-2 YUMM1.7 and B16-BL6 cells. n = 3 biological replicates for all conditions. c, qPCR analysis of B16-BL6 or YUMM1.7 cells treated with vehicle (n = 2 biological replicates for B16-BL6, n = 3 biological replicates for YUMM1.7) or exogenous IFNβ (10 ng/mL) (n = 3 for B16-BL6 and YUMM1.7) for 24 h. d, qPCR analysis of sgNTC and sgTimm50 EO771 and CT26 cells. n = 3 biological replicates for all conditions. e, Immunoblot analysis of sgNTC and sgTimm50 EO771 cells. n = 3 biological replicates per condition, from an experiment performed once. f, Strategy for the generation of cell lines used to investigate the effects of acute Timm50 depletion. g, Immunoblot analysis of sgNTC and sgTimm50 B16-BL6 and YUMM1.7 TIMM50FLAG cell lines, cultured in 100 ng/mL doxycycline or in doxycycline-free media for the indicated durations. The experiment was performed once. h, qPCR analysis of sgNTC and sgTimm50 YUMM1.7 TIMM50FLAG cells, cultured for 9 days without doxycycline, then cultured with or without 100 ng/mL doxycycline for an additional 3 days. n = 3 biological replicates per condition. i, Representative density plots depicting the gating strategy used to identify singlet cells for analysis in Fig. 2f. j, Immunoblot analysis of sgNTC or sgTimm50 YUMM1.7 TIMM50FLAG cells, transduced with empty vector or an ovalbumin (OVA) overexpression vector. The experiment was performed once. Data are mean ± s.d. (c, d, h). Statistical analysis was performed on log2-transformed fold change values using unpaired t-tests with Holm-Šidak correction for multiple comparisons (c (YUMM1.7 only), d), or on log2-transformed fold change values using two-way ANOVA with Tukey’s multiple comparisons test (h). For clarity, only relevant comparisons are highlighted. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns, not significant. For immunoblot source data, see Supplementary Fig. 1. Exact p-values are provided in source data.

Source data

Extended Data Fig. 4 Dissecting the contributions of TREX1, cGAS-STING, and MAVS to cytosolic mtDNA signaling.

a, Immunoblot analysis of pellet and supernatant fractions from YUMM1.7 cells following solubilization with the indicated concentrations of digitonin. b, Immunoblot analysis of sgNTC or sgTimm50 YUMM1.7 TIMM50FLAG cells, with additional transduction of sgTrex1. Cells were cultured without doxycycline for 10 days. c,d, Immunoblot (c) or qPCR (d) analysis of sgNTC or sgTimm50 YUMM1.7 TIMM50FLAG cells, transduced with empty vector (EV) or a TREX1 overexpression vector. Cells were cultured without doxycycline for 10 days. n = 3 biological replicates for qPCR analysis. e, Immunoblot analysis of B16-BL6 and YUMM1.7 cells transduced with sgNTC or sgRNAs targeting Cgas, Mavs, and Sting. f, qPCR analysis of sgNTC, sgCgas, and sgMavs B16-BL6 cells transfected with non-targeting siRNA (NTC) or Timm23-targeting siRNA as indicated. n = 3 biological replicates for all conditions. g, qPCR analysis of sgNTC, sgCgas, and sgMavs YUMM1.7 cells transfected with non-targeting siRNA (NTC) or Timm50-targeting siRNA as indicated. n = 3 biological replicates for all conditions. h,i, Immunoblot (h) or qPCR (i) analysis of sgNTC or sgMavs YUMM1.7 cells transfected with control G3-YSD or G3-YSD (0.5 μg/mL) for 48 h. n = 3 biological replicates for qPCR analysis. j,k, Immunoblot (j) or qPCR (k) analysis of sgNTC or sgMavs YUMM1.7 cells treated with vehicle or exogenous IFNβ (10 ng/mL) for 24 h. n = 3 biological replicates for qPCR analysis. l, qPCR analysis of B16-BL6 cells transduced with sgNTC or sgRNA targeting Ifnar1, treated for 24 h with exogenous IFNβ (10 ng/mL). n = 3 biological replicates for all conditions. m, qPCR analysis of B16-BL6 cells transduced with sgNTC or sgRNA targeting Ifnar1, transfected with non-targeting siRNA (NTC) or Timm23-targeting siRNA as indicated. n = 3 biological replicates for all conditions. Data are mean ± s.d. Statistical analysis was performed on log2-transformed fold change values using one-way ANOVA with Tukey’s multiple comparisons test (d, f, i, k, l, m), or on log2-transformed fold change values using two-way ANOVA with Tukey’s multiple comparisons test (g). For clarity, only relevant comparisons are highlighted. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns, not significant. For immunoblot source data, see Supplementary Fig. 1. Exact p-values are provided in source data.

Source data

Extended Data Fig. 5 Delineation of the mtDNA release pathway following Timm50 depletion.

a, qPCR analysis of sgNTC or sgTimm50 YUMM1.7 TIMM50FLAG cells, treated as indicated with ruxolitinib (10 μM), GSK8612 (5 μM), MRT67307 (10 μM), VBIT-4 (10 μM), or cyclosporin A (1 μM). Cells were cultured for 10 days in the absence of doxycycline; compound treatments were applied for the final 24 h. n = 3 biological replicates per condition b, qPCR analysis of B16-BL6 cells transfected with a non-targeting siRNA (NTC) or Timm23-targeting siRNA and treated with VBIT-4 (10 μM), or cyclosporin A (1 μM). n = 3 biological replicates per condition. c,d, Immunoblot (c) or qPCR (d) analysis of sgNTC or sgTimm50 YUMM1.7 TIMM50FLAG cells, with additional transduction of sgGsdmd, sgGsdme, or sgBak1 as indicated. Cells were cultured without doxycycline for 10 days. n = 3 biological replicates per condition. e, Immunoblot analysis of sgNTC or sgTimm50 YUMM1.7 TIMM50FLAG cells, cultured without doxycycline for 10 days. The staurosporine sample consisted of parental YUMM1.7 cells treated with 1 μM staurosporine for 4 h. f,g, Wild-type (WT) or Bax/Bak1 DKO MEFs were transduced with non-targeting sgRNA (NTC) or an sgRNA targeting Timm50 and characterized by immunoblotting (f) and qPCR (with Bax/Bak DKO MEFs) (g). n = 3 biological replicates for all conditions. Data are mean ± s.d. Statistical analysis was performed on log2-transformed fold change values using one-way ANOVA with Tukey’s multiple comparisons test (a, b, d), or on log2-transformed fold change values using multiple unpaired t tests with Holm-Šidak multiple comparisons test (g). For clarity, only relevant comparisons are highlighted. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns, not significant. For immunoblot source data, see Supplementary Fig. 1. Exact p-values are provided in source data.

Source data

Extended Data Fig. 6 Perturbation of MDV biogenesis and trafficking pathways influence type I IFN production following Timm50 depletion.

a, Immunoblot analysis of YUMM1.7 cells transduced with sgNTC or sgRNAs targeting Snx9 and Rab9a. This experiment was performed once. b, qPCR analysis of sgNTC, sgSnx9 and sgRab9a YUMM1.7 cells transfected as indicated with non-targeting siRNA (NTC) or siRNA targeting Timm50. n = 3 biological replicates per condition. c, Immunoblot analysis of sgNTC, sgSnx9 and sgRab9a YUMM1.7 cells transfected with control G3-YSD or G3-YSD (0.5 μg/mL), or treated with vehicle or IFNβ (10 ng/mL). Treatments were applied for 24 h. This experiment was performed once. d, Immunoblot analysis of YUMM1.7 cells transduced with sgNTC or sgRNAs targeting Vps35, Rab5a, Rab7, or Stx17. This experiment was performed once, using two independent sgRNAs per targeted gene. Similar results were observed for the two independent sgRNAs tested for each gene. e,f, Immunoblot (e) or qPCR (f) analysis of sgNTC or sgTimm50 YUMM1.7 TIMM50FLAG cells, with additional transduction of sgRab5a, sgRab7, or sgStx17 as indicated. Cells were cultured for 10 days without doxycycline. n = 3 biological replicates for all conditions. g, qPCR analysis of YUMM1.7 cells transduced with a non-targeting sgRNA (sgNTC) or sgRNAs targeting Vps35, Rab5a, Rab7, or Stx17. n = 3 biological replicates for all conditions. Data are mean ± s.d. Statistical analysis was performed on log2-transformed fold change values using one-way ANOVA with Tukey’s multiple comparisons test (b,f). For clarity, only relevant comparisons are highlighted. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns, not significant. For immunoblot source data, see Supplementary Fig. 1. Exact p-values are provided in source data.

Source data

Extended Data Fig. 7 Characterization of proteomic and metabolic defects that occur following Timm50 depletion.

a, Principal component analysis of proteomic datasets from sgNTC or sgTimm50 YUMM1.7 TIMM50FLAG cells, at day 6 or day 10 following removal of doxycycline. n = 4 per condition. b, Immunoblot analysis of B16-BL6 and YUMM1.7 cells transduced with non-targeting sgRNA or sgRNAs targeting the indicated genes, which were selected based on analysis of proteomics data. c, Abundance of selected metabolites from sgNTC or sgTimm50 YUMM1.7 TIMM50FLAG cells, cultured for 1 or 3 h in [U-13C6]-glucose. Cells were cultured in the absence of doxycycline for 8 days. n = 4 biological replicates per condition. d, Volcano plot depicting metabolite abundance in sgTimm50 (n = 4) relative to sgNTC (n = 4) YUMM1.7 TIMM50FLAG cells, 6 days after removal of doxycycline. Vertical dotted lines indicate 1.5-fold up or down-regulation, while the horizontal dotted line represents p = 0.05. e, qPCR analysis of sgNTC or sgTimm50 YUMM1.7 TIMM50FLAG cells cultured without doxycycline for 10 days, with the addition of 2 mM n-acetylcysteine (NAC) or 100 nM mitoquinone mesylate (MitoQ) for 2 days before harvest. n = 3 biological replicates per condition. f, qPCR analysis of YUMM1.7 cells transfected with NTC siRNA or siRNA targeting Timm50, treated with 2 mM n-acetylcysteine (NAC) or 10 μM Mito-TEMPO. Cells were harvested 4 days after siRNA transfection, and treatments were applied for the final 3 days. n = 2 biological replicates per condition. g, qPCR analysis of B16-BL6 cells transfected with NTC siRNA or siRNA targeting Timm23, treated with 2 mM n-acetylcysteine (NAC), 10 μM Mito-TEMPO, 5 μM ruxolitinib, or 5 μM GSK8612. Cells were harvested 4 days after siRNA transfection, and treatments were applied for the final 3 days. n = 2 biological replicates per condition. h, qPCR analysis of YUMM1.7 cells treated with rotenone (10 nM or 50 nM) or antimycin A (20 nM) for 48 h. n = 3 biological replicates per condition. Data are mean ± s.d. Statistical analysis was performed using unpaired two-tailed t-tests with Welch’s correction (c,d), or on log2-transformed fold change values using two-way ANOVA with Tukey’s multiple comparisons test (e,h). For clarity, only relevant comparisons are highlighted. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns, not significant. For immunoblot source data, see Supplementary Fig. 1. Exact p-values are provided in source data.

Source data

Extended Data Fig. 8 Delineation of TFAM and the mitochondrial proteostasis machinery involvement in the Timm50 depletion-driven phenotype.

a,b, Principal component analysis of proteomics datasets from isolated mitochondria (a) or cytosolic fractions (b) derived from sgNTC or sgTimm50 YUMM1.7 TIMM50FLAG cells, cultured for 10 days without doxycycline. n = 3 biological replicates per condition. c,d, Immunoblot (c) or qPCR (d) analysis of sgNTC and sgTimm50 YUMM1.7 TIMM50FLAG cells transduced with empty vector or a TFAM overexpression vector. Cells were cultured for 10 days without doxycycline. n = 3 biological replicates for qPCR samples. e, Principal component analysis of solubility proteomics datasets (after Triton X-100 fractionation) from sgNTC or sgTimm50 YUMM1.7 TIMM50FLAG cells, cultured without doxycycline for 10 days. n = 3 biological replicates per condition. Samples are colored by genotype and shaped according to fraction (pellet or supernatant). f,g, Immunoblot (f) or qPCR (g) analysis of YUMM1.7 cells transduced with sgNTC or sgRNAs targeting Clpx, Clpp, Afg3l2, Lonp1, or Timm50. n = 3 biological replicates for qPCR samples. h, Representative transmission electron microscopy images of sgNTC and sgTimm50 YUMM1.7 and B16-BL6 TIMM50FLAG cells, cultured for 10 days without doxycycline. This experiment was performed once. Data are mean ± s.d. Statistical analysis was performed on log2-transformed fold change values using two-way ANOVA with Tukey’s multiple comparisons test (d), or on log2-transformed fold change values using one-way ANOVA with Dunnett’s multiple comparisons test (g). For clarity, only relevant comparisons are highlighted. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns, not significant. For immunoblot source data, see Supplementary Fig. 1. Exact p-values are provided in source data.

Source data

Supplementary information

Supplementary Figure 1 (download PDF )

Uncropped western blots, labelled by figure and panel

Reporting Summary (download PDF )

Supplementary Tables 1–9 (download ZIP )

Supplementary Table 1. Processed RNA-sequencing data from sgNTC and sgTimm50 YUMM1.7 tumors inoculated in C57BL/6 mice. Supplementary Table 2. Processed RNA-sequencing data from sgNTC and sgTimm50 YUMM1.7 and B16-BL6 cells, cultured in vitro. Supplementary Table 3. Processed whole-cell proteomics data from YUMM1.7 TIMM50FLAG sgNTC and sgTimm50 cells, cultured without doxycycline for 6 or 10 days. Supplementary Table 4. Processed metabolomics data depicting scaled values for metabolites of interest from YUMM1.7 TIMM50FLAG sgNTC and sgTimm50 cells labelled for 1 or 3 hours with [U-13C6]-glucose. Supplementary Table 5. Processed whole-cell metabolomics data from YUMM1.7 TIMM50FLAG sgNTC and sgTimm50 cells, cultured for 6 days without doxycycline. Supplementary Table 6. Processed mitochondrial proteomics data from YUMM1.7 TIMM50FLAG sgNTC and sgTimm50 cells. Supplementary Table 7. Processed cytosol proteomics data from YUMM1.7 TIMM50FLAG sgNTC and sgTimm50 cells. Supplementary Table 8. Processed solubility proteomics data obtained from Triton X-100 solubilized mitochondria isolated from YUMM1.7 TIMM50FLAG sgNTC and sgTimm50 cells. Supplementary Table 9. List of sgRNA sequences, siRNA sequences, antibodies, and qPCR primers sequences used in the study.

Peer Review File (download PDF )

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jackson, T.D., Palozzi, J.M., McGann, C.D. et al. Mitochondrial protein import defects enhance tumour immunogenicity. Nature (2026). https://doi.org/10.1038/s41586-026-11249-1

Download citation

  • Received: 30 October 2025

  • Accepted: 05 October 2026

  • Published: 11 November 2026

  • Version of record: 11 November 2026

  • DOI: https://doi.org/10.1038/s41586-026-11249-1

来源:Nature 综合主刊 · nature.com